治疗后感染性炎症性关节炎的管理
Hailey Baker1, J Kennedy Amaral2, Robert T Schoen1
1Section of Rheumatology, Allergy, and Immunology, Yale School of Medicine.
Current opinion in rheumatology
|February 27, 2024
概括
由各种病原体引发的后感染性炎症性关节炎,可以从轻度到重度的慢性疾病. 管理策略正在不断发展,新的疾病修饰治疗方法为患者提供了更多的选择.
科学领域:
- 类风湿病学 类风湿病学
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
背景情况:
- 后感染性炎症性关节炎是由各种病原体 (细菌,病毒,真菌,寄生虫) 引起的.
- 虽然急性感染治疗至关重要,但有些病例会发展为慢性关节炎.
- 这种情况呈现出从自我限制性关节痛到严重的耐火性关节炎的频谱,需要长期管理.
研究的目的:
- 探索后感染性炎症性关节炎的全谱.
- 为有效的管理策略提供洞察力.
- 总结了常见形式的后感染性炎症性关节炎的传统和新型疗法.
主要方法:
- 关于后感染性炎症性关节炎的当前文献的综述.
- 对急性和慢性阶段治疗方法的分析.
- 讨论新出现的治疗选择,包括生物药物和有针对性的合成DMARDs.
主要成果:
- 大多数感染后炎症性关节炎病例在经过急性感染治疗后自我限制,以症状管理.
- 一部分患者患有慢性,难以管理的感染后炎症性关节炎.
- 扩展的治疗选择现在包括生物药物和针对性合成DMARDs用于耐火病例.
结论:
- 生物和向合成疾病修饰性抗风湿药物 (DMARDs) 的可用性扩大了治疗选择.
- 有效的管理需要了解不同的临床表现和致病机制.
- 本综述提供了对后感染性炎症性关节炎的当前和新兴治疗策略的见解.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Inflammatory Response
2.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Tonsillitis II: Management
111
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
111
Pleural Effusion II: Symptoms and Management
173
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
173


